rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DNTH
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Dianthus Therapeutics evp Savitz sells $11.2M in stock
      Nov 13Investing.comDNTH
      Dianthus Therapeutics (DNTH) Stock May Look Stretched As Pipeline Progress Draws Focus

      Dianthus Therapeutics has turned into a striking outperformer, with a very large 3 year gain putting fresh attention on whether the share price still lines up with what its balance sheet supports. With that kind of move already on the table, the question now is how today’s valuation stacks up against the book value sitting behind each share. Over the past 3 years the stock has returned roughly 7x, which puts a lot of weight on whether the current market value can be explained by what the...

      Nov 10Yahoo FinanceDNTH
      Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?
      Nov 9Yahoo FinanceDNTH
      Dianthus Therapeutics earnings beat by $0.13, revenue topped estimates
      Nov 5Investing.comDNTH
      Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
      Nov 4Yahoo FinanceDNTH
      Dianthus Therapeutics earnings up next as trial data looms
      Nov 4Investing.comDNTH
      Roth/MKM initiates Dianthus Therapeutics stock at buy on drug profile
      Oct 27Investing.comDNTH
      Roth Capital Initiates Coverage on Dianthus Therapeutics With Buy Rating
      Oct 27Yahoo FinanceDNTH
      Why is Dianthus Therapeutics stock gaining today?
      Oct 27Investing.comDNTH
      Dianthus Therapeutics (DNTH) Stock May Be Above Fair Value Following Its 5x Run
      Oct 20Yahoo FinanceDNTH
      Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion
      Oct 13Yahoo FinanceDNTH
      Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter - Align Technology (NASDAQ:ALGN)

      Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.

      Oct 6BenzingaALGNDNTHOCUL
      William Blair refreshes its analyst conviction list (SPY:NYSEARCA)

      William Blair’s October conviction list: 6 new stocks (REAL, CHYM, DAVE, RELY, DNTH, NTSK) and 4 removals—key catalysts, valuation.

      Oct 1Seeking AlphaCHYMDAVEWDNTH
      Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?

      Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration. The capital raise comes after a sharp pullback in Dianthus Therapeutics' share price. The stock fell 4.99% over the last session, 8.83% across the past week and 15.11% over 30 days. However, the 90-day share price return of 2.04% and a year-to-date share price gain of 135.48% suggest that momentum has...

      Sep 24Yahoo FinanceDNTH
      Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run

      Dianthus Therapeutics has delivered a very large 3 year return, which puts a lot of focus on whether the current share price still lines up with what its balance sheet actually supports. With the stock last closing at US$93.44, the open question is how that level stacks up against the book value backing each share. Over the past 3 years the stock has gained roughly 7x. Anyone looking at Dianthus Therapeutics now has to ask whether that kind of move is still grounded in the company’s...

      Sep 24Yahoo FinanceDNTH
      JPMorgan initiates Dianthus stock at Overweight, $135 target
      Sep 11Investing.comDNTH
      JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating

      Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $139.36, accordin

      Sep 11Yahoo FinanceDNTH
      Dianthus Therapeutics at Cantor conference: pipeline gains speed
      Sep 10Investing.comDNTH
      TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating
      Sep 9Yahoo FinanceDNTHFHTX
      Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement
      Sep 6Seeking AlphaDNTH
      Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen

      On August 4, Dianthus Therapeutics (NASDAQ:DNTH) reported second-quarter 2026 results alongside a stack of pipeline updates that touched nearly every program the company runs. For a clinical-stage biotech with no approved product yet, the update reads less like a routine earnings drop and more like a status report on three separate autoimmune disease bets happening […]

      Sep 5Yahoo FinanceDNTH
      Dianthus stock gains new Buy from Citi (DNTH:NASDAQ)
      Sep 4Seeking AlphaDNTH
      Citigroup Initiates Dianthus Therapeutics at Buy With $156 Price Target

      Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $139.36, accordin

      Sep 4Yahoo FinanceDNTH
      Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on September 1, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to ac

      Sep 2Yahoo FinanceDNTH
      Dianthus Therapeutics to Participate in Three Investor Conferences During September
      Sep 1Yahoo FinanceDNTH
      Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
      Aug 25Seeking AlphaDNTH

      This is the newest page. Registered accounts read further back.